mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)
In patients with locally advanced rectal cancer and MRI-defined low risk of local recurrence, neoadjuvant mFOLFOX6 + aflibercept was feasible and did not compromise surgery. Survival data were favorable in both arms, but pCR rates were not increased by the addition of aflibercept.
Authors
- Maja Ebert
- Timo Gaiser
- Manfred Welslau (ORCID: https://orcid.org/0000-0002-3103-0312)
- E Fokas
- Claus Rödel (ORCID: https://orcid.org/0000-0001-7409-7093)
- Sebastian Lettmaier (ORCID: https://orcid.org/0000-0001-6805-1558)
- Lisa Kochen
- Christoph Reißfelder (ORCID: https://orcid.org/0000-0003-4591-1046)
- Stefan Kubicka
- Kirsten Merx
- Tobias Dechow (ORCID: https://orcid.org/0000-0001-8976-7328)
- Karoline Krause (ORCID: https://orcid.org/0000-0001-9711-9654)
- Ludwig Fischer von Weikersthal (ORCID: https://orcid.org/0000-0002-9128-0807)
- M. Ghadimi (ORCID: https://orcid.org/0009-0005-6674-3688)
- Florian Herrle
- Christoph Burkart
- R-D Hofheinz
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Universitätsklinikum Erlangen (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103703
- Citations
- 3
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Astellas Pharma
- Deutsche Krebshilfe
- Servier
- AIO-Studien
- Sanofi-Aventis Deutschland